A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.
Mol Ther. 2020 Jan 8;28(1):52-63. doi: 10.1016/j.ymthe.2019.10.009. Epub 2019 Oct 15.
Mol Ther. 2020.
PMID: 31704085
Free PMC article.